Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GLP1R | P43220 | 8/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26865987 | 0.97 | TSHR (0.36) | MEN1KMT2AGLP1RKDM4EPOLB | |
| SCHEMBL26866001 | 0.90 | TSHR (0.38) | MEN1KMT2AGLP1RKDM4EPOLB | |
| SCHEMBL23446933 | 0.87 | MEN1 (0.38) | MEN1KMT2AGLP1RTSHRRECQL | |
| SCHEMBL23872011 | 0.87 | MEN1 (0.44) | MEN1KMT2AGLP1RKDM4EPOLB | |
| SCHEMBL21925758 | 0.86 | GLP1R (0.39) | MEN1KMT2AGLP1RKDM4EPOLB | |
| SCHEMBL25963095 | 0.86 | TSHR (0.42) | MEN1KMT2AGLP1RKDM4EPOLB | |
| SCHEMBL26865995 | 0.83 | MEN1 (0.41) | MEN1KMT2AGLP1RKDM4EPOLB | |
| SCHEMBL13253969 | 0.82 | MEN1 (0.45) | MEN1KMT2AKDM4EPOLBTDP1 | |
| SCHEMBL24608219 | 0.82 | KDM4E (0.40) | MEN1KMT2AKDM4EPOLBTDP1 | |
| SCHEMBL16134044 | 0.82 | TSHR (0.49) | MEN1KMT2ATSHRALDH1A1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372508-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | OLIX US, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023225650-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | OLIX US, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372508-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | DNPEP, LNPEP, FGB | MEN1 2970/4885KMT2A 4010/4885GLP1R 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.